

References

I-126

1. Chotirmall S, Al-Alawi M, McEnery T, et al. Alpha-1 proteinase inhibitors for the treatment of alpha-1 antitrypsin deficiency: safety, tolerability, and patient outcomes. *Ther Clin Risk Manag.* 2015;11:143–151.
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated
3. The American Thoracic Society. American Thoracic Society/European Respiratory Society Statement: Standards for the diagnosis and management of individuals with Alpha-1 antitrypsin deficiency.
4. Henao M, Craig T. Understanding alpha-1 antitrypsin deficiency: A review with an allergist's outlook. *Allergy And Asthma Proceedings.* 2017; 38(2):98-107.
5. Vogelmeier C, Criner G, Agustí A, et al. *Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. American Journal Of Respiratory And Critical Care Medicine.* 2017; 195(5):557-582.
6. Sorrells S, Camprubi S, Griffin R, et al. SPARTA clinical trial design: Exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1- antitrypsin deficiency. *Resp Med.* 2015;490-499.
7. Polinski JM, Kowal MK, Gagnon M, et al. Home infusion: Safe clinically effective, patient preferred, and cost saving. 2016.
8. MCG™ Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT: CMT-0009(SR).
9. Micromedex®Solutions Compendia. 2020. Alpha-1 Proteinase Inhibitors.
10. Clinical Pharmacology Compendia [database online]. Tampa FL: Gold Standard, Inc. Alpha-1 Proteinase Inhibitors. 2020.

11. Kueppers F, Andrade MD, Xu Q, Dunbrack RL, Kim J, Sanders CL. Protein modeling to assess the pathogenicity of rare variants of SERPINA1 in patients suspected of having Alpha 1 Antitrypsin Deficiency. *BMC Med Genet.* 2019. 20(1):125.
12. Wells AD, Woods A, Hilleman DE, Malesker MA. Alpha-1 antitrypsin replacement in patients with COPD. *P&T: A Peer-Reviewed Journal for Managed Care & Formulary Management.* 2019;44(7):412-415.
13. Brantly ML, Lascano JE, Shahmohammadi A. Intravenous alpha-1 antitrypsin therapy for alpha-1 antitrypsin deficiency: the current state of the evidence. *Chronic Obstr Pulm Dis.* 2019;6(1):100-114.
14. Sandhaus RA, Turino G, Brantly ML, et al. The diagnosis and management of alpha-1 antitrypsin deficiency in the adult. *Chronic Obstr Pulm Dis.* 2016; 3(3): 668-682.
15. Glassia (Alpha1-proteinase inhibitor (human)) [package insert]. Baxalta US Inc. Lexington, MA. Revised 06/2017.
16. Prolastin-C Liquid (Alpha1-proteinase inhibitor [human]) [package insert]. Grifols Therapeutics, LLC. Research Triangle Park, NC. Revised 08/2018.
17. Aralast (Alpha1-proteinase inhibitor (human)) [package insert]. Baxalta U.S. Inc., Lexington, MA. Revised 12/2018.
18. Zemaira (Alpha1-proteinase inhibitor (human)) [package insert]. CSL Behring, LLC. Kankakee, IL. Revised 04/2019.
19. [Alpha 1-Proteinase Inhibitor (Human)] In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated April 1, 2009.